Helen Torley
Chief Executive Officer chez HALOZYME THERAPEUTICS, INC.
Fortune : 28 M $ au 31/03/2024
Profil
Helen I. Torley occupe le poste de présidente, directrice générale et directrice chez Halozyme Therapeutics, Inc. Elle est également membre du conseil d'administration de Quest Diagnostics, Inc., directrice et membre du conseil d'administration de la section santé de la Biotechnology Innovation Organization et membre du Royal College of Physicians. Dans le passé, elle a été vice-présidente et directrice générale de la santé osseuse aux États-Unis chez Amgen, Inc. et directrice commerciale et vice-présidente exécutive d'Onyx Pharmaceuticals, Inc. (une filiale d'Amgen, Inc.), vice-présidente des affaires médicales de Novartis, Inc. et vice-présidente des affaires médicales de Sandoz SA, ainsi que vice-présidente des ventes de produits cardiovasculaires et métaboliques du Bristol-Myers Squibb World Wide Medicines Group. Elle a obtenu un diplôme de premier cycle à l'université de Glasgow.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 26/02/2024 | 676 744 ( 0,53% ) | 28 M $ | 31/03/2024 |
Postes actifs de Helen Torley
| Sociétés | Poste | Début |
|---|---|---|
| HALOZYME THERAPEUTICS, INC. | Chief Executive Officer | 06/01/2014 |
| ANTARES PHARMA, INC. | Director/Board Member | 24/05/2022 |
| The Royal College of Physicians | Corporate Officer/Principal | - |
Biotechnology Innovation Organization
 Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers. | Director/Board Member | - |
Anciens postes connus de Helen Torley
| Sociétés | Poste | Fin |
|---|---|---|
| QUEST DIAGNOSTICS INCORPORATED | Director/Board Member | 18/05/2022 |
| RELYPSA INC | Director/Board Member | 01/09/2016 |
Onyx Pharmaceuticals, Inc.
 Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | Chief Operating Officer | 15/12/2011 |
| AMGEN INC. | Corporate Officer/Principal | 01/01/2011 |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 01/01/2002 |
Formation de Helen Torley
| University of Glasgow | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 4 |
|---|---|
| AMGEN INC. | Health Technology |
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| QUEST DIAGNOSTICS INCORPORATED | Health Services |
| HALOZYME THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 6 |
|---|---|
Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | Health Technology |
Antares Pharma, Inc.
 Antares Pharma, Inc. Pharmaceuticals: MajorHealth Technology Antares Pharma, Inc. is a specialty pharmaceutical company, which engages in the development and commercialization of pharmaceutical products and technologies in targeted therapeutic areas. Its products include XYOSTED injection, OTREXUP injection for subcutaneous use, and Sumatriptan injection. The company was founded in February 1979 and is headquartered in Ewing, NJ. | Health Technology |
Novartis, Inc.
 Novartis, Inc. Pharmaceuticals: MajorHealth Technology Part of Novartis AG, Novartis, Inc. is a private company based in San Francisco. | Health Technology |
Biotechnology Innovation Organization
Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers. | Commercial Services |
Relypsa, Inc.
 Relypsa, Inc. Pharmaceuticals: MajorHealth Technology Relypsa, Inc. operates as a bio-pharmaceutical company, which engages in the development and commercialization of late-stage medicines in the iron deficiency, nephrology, and cardio-renal therapeutic areas. It offers Veltassa, a potassium binder approved for the treatment of hyperkalemia. The company was founded by Jerry M. Buysse, Gerrit Klaerner, Michael Burdick, Jay P. Shepard, Detlef F. Albrecht, George Tyson, Sandra I. Coufal and Vic Ciaravino on October 29, 2007 and is headquartered in Redwood City, CA. | Health Technology |
| Sandoz SA |
